Bronchiectasis and Nontuberculous Mycobacterial Disease

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 283-295

  Griffith, David E ^a   Aksamit, Timothy R ^b  

^a Health Science Center   (United States)

^b Mayo Clinic   (United States)

Author keywords

Bronchiectasis; Mycobacterium abscessus; Mycobacterium avium complex; Nontuberculous mycobacteria

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE; GENE MUTATION; HOST PATHOGEN INTERACTION; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LUNG DISEASE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR PATHOLOGY; MONOTHERAPY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM SZULGAI; NONHUMAN; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

BRONCHIECTASIS; HUMANS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PRACTICE GUIDELINES AS TOPIC;

EID: 84861565503     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.02.002     Document Type: Review

References (59)

1. Forrest Gump 1994, Paramount Pictures.
2. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979, 119(1):107-159.
3. Prince D.S., Peterson D.D., Steiner R.M., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989, 321(13):863-868.
4. Rosenzweig D.Y. Pulmonary mycobacterial infections due to Mycobacterium intreacellulare-avium complex (clinical features and course in 100 consecutive cases). Chest 1979, 75:115-119.
5. Ahn C.H., McLarty J.W., Ahn S.S., et al. Diagnostic criteria for pulmonary disease caused by Mycobacterium kansasii and Mycobacterium intracellulare. Am Rev Respir Dis 1982, 125(4):388-391.
6. Valero G., Peters J., Jorgensen J.H., et al. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review. Am J Respir Crit Care Med 1995, 152(5 Pt 1):1555-1557.
7. Griffith D.E., Girard W.M., Wallace R.J. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993, 147(5):1271-1278.
8. Griffith D.E., Brown-Elliott B.A., Wallace R.J. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003, 37(9):1178-1182.
9. Polverosi R., Guarise A., Balestro E., et al. High-resolution CT of nontuberculous mycobacteria pulmonary infection in immunocompetent, non-HIV-positive patients. Radiol Med 2010, 115(2):191-204.
10. Grenier P., Maurice F., Musset D., et al. Bronchiectasis: assessment by thin-section CT. Radiology 1986, 161(1):95-99.
11. Joharjy I.A., Bashi S.A., Adbullah A.K. Value of medium-thickness CT in the diagnosis of bronchiectasis. AJR Am J Roentgenol 1987, 149(6):1133-1137.
12. Nicotra M.B., Rivera M., Dale A.M., et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995, 108(4):955-961.
13. Pasteur M.C., Helliwell S.M., Houghton S.J., et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162(4 Pt 1):1277-1284.
14. Scala R., Aronne D., Palumbo U., et al. Prevalence, age distribution and aetiology of bronchiectasis: a retrospective study on 144 symptomatic patients. Monaldi Arch Chest Dis 2000, 55(2):101-105.
15. Wickremasinghe M., Ozerovitch L.J., Davies G., et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 2005, 60(12):1045-1051.
16. Fowler S.J., French J., Screaton N.J., et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006, 28(6):1204-1210. [erratum in: Eur Respir J 2007;29(3):614-5].
17. Olivier K.N., Weber D.J., Lee J.H., et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003, 167(6):835-840. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group.
18. Olivier K.N., Weber D.J., Wallace R.J., et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167(6):828-834. Nontuberculous Mycobacteria in Cystic Fibrosis Study Group.
19. Griffith D.E. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med 2003, 167(6):810-812.
20. Noone P.G., Leigh M.W., Sannuti A., et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004, 169(4):459-467.
21. Griffith D.E., Aksamit T., Brown-Elliott B.A., ATS Mycobacterial Diseases Subcommittee, American Thoracic Society; Infectious Disease Society of America, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416. [review. erratum in: Am J Respir Crit Care Med 2007;175(7):744-5].
22. Fujita J., Ohtsuki Y., Shigeto E., et al. Pathological analysis of the cavitary wall in Mycobacterium avium intracellulare complex pulmonary infection. Intern Med 2002, 41(8):617-621.
23. Fujita J., Ohtsuki Y., Shigeto E., et al. Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex. Respir Med 2003, 97(8):933-938.
24. Tanaka E., Lee W.J., Juba Y., et al. Computed tomography findings of pulmonary infections caused by Mycobacterium avium complex in patient without predisposing conditions. Am Rev Respir Dis 1994, 149:A108.
25. Kim R.D., Greenberg D.E., Ehrmantraut M.E., et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178(10):1066-1074.
26. Ziedalski T.M., Kao P.N., Henig N.R., et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006, 130(4):995-1002.
27. Chan E.D., Kaminska A.M., Gill W., et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria2 and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007, 39(8):690-696.
28. Kim J.S., Tanaka N., Newell J.D., et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest 2005, 128(6):3863-3869.
29. Mai H.N., Hijikata M., Inoue Y., et al. Pulmonary Mycobacterium avium complex infection associated with the IVS8-T5 allele of the CFTR gene. Int J Tuberc Lung Dis 2007, 11(7):808-813.
30. Bienvenu T., Sermet-Gaudelus I., Burgel P.R., et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010, 181(10):1078-1084.
31. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290(13):1749-1756. Macrolide Study Group.
32. Albert R.K., Connett J., Bailey W.C., COPD Clinical Research Network, et al. Azithromycin for prevention of exacerbation of COPD. N Engl J Med 2011, 365:689-698.
33. Feazel L.M., Baumgartner L.K., Peterson K.L., et al. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci U S A 2009, 106:16393-16399.
34. Nishiuchi Y., Maekura R., Kitada S., et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis 2007, 45(3):347-351.
35. Falkinham J.O. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011, 17(3):419-424.
36. Falkinham J.O., Iseman M.D., de Haas P., et al. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health 2008, 6:209-213.
37. Marras T.K., Wallace R.J., Koth L.L., et al. Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005, 127(2):664-671.
38. Tanaka E., Kimoto T., Tsuyuguchi K., et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999, 160:866-872.
39. Hartman T.E., Swensen S.J., Williams D.E. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology 1993, 187(1):23-26.
40. Swensen S.J., Hartman T.E., Williams D.E. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994, 105(1):49-52.
41. Patz E.F., Swensen S.J., Erasmus J. Pulmonary manifestations of nontuberculous Mycobacterium. Radiol Clin North Am 1995, 33(4):719-729.
42. Park S., Suh G.Y., Chung M.P., et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008, 102:437-442.
43. Kitada S., Kobayashi K., Ichiyama S. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 2008, 177:793-797. MAC Serodiagnosis Study Group.
44. Wallace R.J., Brown B.A., Griffith D.E., et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996, 153:1766-1772.
45. Kobashi Y., Abe M., Mouri K., et al. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease. J Infect 2010, [Epub ahead of print].
46. Kobashi Y., Yoshida K., Miyashita N., et al. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 2006 Aug, 12(4):195-202.
47. Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001, 56(3):167-172.
48. Nash K.A., Brown-Elliott B.A., Wallace R.J. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53(4):1367-1376.
49. Nash K.A., Andini N., Zhang Y., et al. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006, 50(10):3476-3478.
50. Lam P.K., Griffith D.E., Aksamit T.R., et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 173(11):1283-1289.
51. Kobashi Y., Matsushima T., Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007, 101:130-138.
52. Griffith D.E., Brown-Elliott B.A., Langsjoen B., et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 174(8):928-934.
53. Field S.K., Cowie R.L. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003, 124:1482-1486.
54. Davis K.K., Kao P.N., Jacobs S.S., et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007, 7:2.
55. Wallace R.J., Zhang Y., Brown-Elliott B.A., et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002, 186(2):266-273.
56. Jeon K., Kwon O., Lee N., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896-903.
57. Jarand J., Levin A., Zhang L., et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011, 52(5):565-571.
58. Hill A.T., Pasteur M., Cornford C., et al. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011, 20(2):135-140.
59. Schönfeld N. The mycobacterial mystery. Eur Respir J 2006, 28(6):1076-1078.